Treatment for Nonalcoholic Steatohepatitis

Phase-Based Progress Estimates
Mercy Medical Center, Inc, Baltimore, MD
Nonalcoholic Steatohepatitis+2 More
All Sexes
What conditions do you have?

Study Summary

Collection of clinical and genetic data to help identify individuals that carry genetic variants of known importance in Non-alcoholic Steatohepatitis (NASH)

Eligible Conditions

  • Nonalcoholic Steatohepatitis
  • Steatohepatitis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Nonalcoholic Steatohepatitis

Study Objectives

2 Primary · 2 Secondary · Reporting Duration: Day 1

Day 1
Distribution of FIB-4 scores across participants with different genotypes of rs738409 in PNPLA3B13
Distribution of fibrosis-4 (FIB-4) scores across participants with different genotypes of rs72613567 in HSD17B13
Genotype frequencies of rs72613567 in Hydroxysteroid 17β dehydrogenase 13 (HSD17B13)
Genotype frequencies of rs738409 in patatin-like phospholipase domain containing 3 (PNPLA3)

Trial Safety

Safety Progress

1 of 3

Other trials for Nonalcoholic Steatohepatitis

Trial Design

0 Treatment Group

8000 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: day 1
Closest Location: Mercy Medical Center, Inc · Baltimore, MD
Photo of Baltimore 1Photo of Baltimore 2Photo of Baltimore 3
N/AFirst Recorded Clinical Trial
0 TrialsResearching Nonalcoholic Steatohepatitis
0 CompletedClinical Trials

Who is running the clinical trial?

Regeneron PharmaceuticalsLead Sponsor
535 Previous Clinical Trials
187,585 Total Patients Enrolled
Clinical Trial ManagementStudy DirectorRegeneron Pharmaceuticals
217 Previous Clinical Trials
78,356 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Imaging modalities to assess historic evidence of NAFLD may be based on thresholds as described in the protocol.
You are fasting for at least 6 months.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.